Skip to main content

REVIEW article

Front. Cell. Infect. Microbiol.
Sec. Microbial Vaccines
Volume 14 - 2024 | doi: 10.3389/fcimb.2024.1501010
This article is part of the Research Topic Vaccine and Infectious Disease Informatics View all 3 articles

Computational Biology and Artificial Intelligence in mRNA Vaccine Design for Cancer Immunotherapy

Provisionally accepted
Saber Imani Saber Imani 1Xiaoyan Li Xiaoyan Li 1Keyi Chen Keyi Chen 1Mehrdad Hashemi Mehrdad Hashemi 2Saloomeh Khoushab Saloomeh Khoushab 2Mazaher Maghsoudloo Mazaher Maghsoudloo 3Xiaoping Li Xiaoping Li 1*
  • 1 Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China
  • 2 Department of Medical Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Alborz, Iran
  • 3 Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Messenger RNA (mRNA) vaccines offer an adaptable and scalable platform for cancer immunotherapy, requiring optimal design to elicit a robust and targeted immune response. Recent advancements in bioinformatics and artificial intelligence (AI) have significantly enhanced the design, prediction, and optimization of mRNA vaccines. This paper reviews technologies that streamline mRNA vaccine development, from genomic sequencing to lipid nanoparticle (LNP) formulation. We discuss how accurate predictions of neoantigen structures guide the design of mRNA sequences that effectively target immune and cancer cells. Furthermore, we examine AI-driven approaches that optimize mRNA-LNP formulations, enhancing delivery and stability. These technological innovations not only improve vaccine design but also enhance pharmacokinetics and pharmacodynamics, offering promising avenues for personalized cancer immunotherapy.

    Keywords: Neo-antigen mRNA vaccines, Lipid nanoparticles, bioinformatics, artificial intelligence, Targeted immunotherapy

    Received: 24 Sep 2024; Accepted: 16 Dec 2024.

    Copyright: © 2024 Imani, Li, Chen, Hashemi, Khoushab, Maghsoudloo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xiaoping Li, Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.